HRS-7249
Asset
GalNAc-conjugated siRNA suppresses APOC3 expression to lower triglycerides.
- Stage
- Phase 2
- Modality
- Oligonucleotide
- Target
- Lipid and ceramide metabolism
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Hyperlipidemia
Phase 2, Recruiting, NCT07799688, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.